Dermira (NASDAQ:DERM) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.05, Morningstar.com reports. The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $0.80 million. Dermira had a negative return on equity of 128.21% and a negative net margin of 761.87%.
NASDAQ DERM traded down $0.62 on Thursday, hitting $11.88. 946,506 shares of the company’s stock were exchanged, compared to its average volume of 1,002,837. The company has a debt-to-equity ratio of 2.49, a current ratio of 4.78 and a quick ratio of 4.78. Dermira has a 52 week low of $6.98 and a 52 week high of $31.42. The stock has a market capitalization of $513.14 million, a PE ratio of -2.71 and a beta of 0.96.
In other Dermira news, Director Matthew K. Fust sold 4,000 shares of the company’s stock in a transaction on Friday, October 19th. The stock was sold at an average price of $13.75, for a total transaction of $55,000.00. Following the completion of the sale, the director now directly owns 14,051 shares in the company, valued at $193,201.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.80% of the stock is owned by corporate insiders.
DERM has been the subject of several recent analyst reports. ValuEngine upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Thursday, November 1st. Zacks Investment Research upgraded Dermira from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Mizuho restated a “hold” rating and set a $10.00 target price on shares of Dermira in a research note on Tuesday, October 2nd. Cantor Fitzgerald set a $20.00 target price on Dermira and gave the stock a “buy” rating in a research note on Monday, August 6th. Finally, BidaskClub upgraded Dermira from a “hold” rating to a “buy” rating in a research note on Friday, September 14th. Four analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $22.86.
COPYRIGHT VIOLATION NOTICE: “Dermira (DERM) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/09/dermira-derm-posts-quarterly-earnings-results-beats-expectations-by-0-05-eps.html.
Dermira, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis.
Further Reading: Trading Strategy
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.